	Srodki Pieniężne I Ekwiwalent		Data
Agios Pharmaceuticals	USD 89.13M	3.58M	2025-12
Alnylam Pharmaceuticals	USD 1.66B	167M	2025-12
Amgen	USD 9.13B	316M	2025-12
Biogen	USD 3.01B	854.3M	2025-12
BioMarin Pharmaceutical	USD 1.25B	36.29M	2025-09
Daiichi Sankyo	JPY 542.16B	97.68B	2025-09
Esperion Therapeutics	USD 92.45M	6.39M	2025-09
Exelixis	USD 482.49M	106.19M	2025-12
Gilead Sciences	USD 7.33B	2.19B	2025-09
Glaxosmithkline	GBP 3.3B	303M	2025-09
Incyte	USD 3.58B	650.78M	2025-12
MacroGenics	USD 80.13M	50.56M	2025-09
Moderna	USD 2.6B	1.46B	2025-12
Novartis	USD 9.56B	2.9B	2025-09
Pfizer	USD 1.34B	295M	2025-09
PTC Therapeutics	USD 984.65M	312.03M	2025-12
Puma Biotechnology	USD 53.52M	1.14M	2025-09
Regeneron Pharmaceuticals	USD 18.87B	16.36B	2025-12
Roche Holding	CHF 7.55B	579M	2025-06
Sangamo BioSciences	USD 38.34M	13.16M	2025-06
Sarepta Therapeutics	USD 613.08M	102.48M	2025-09
Takeda	JPY 654.94B	26.55B	2025-12
TG Therapeutics	USD 178.32M	100.54M	2025-09
Ultragenyx Pharmaceutical	USD 202.51M	36.4M	2025-09
Vanda Pharmaceuticals	USD 84.85M	14.83M	2025-12
Vertex Pharmaceuticals	USD 6.61B	321.1M	2025-12

Puma Biotechnology Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.